HUP0400697A3 - Silensed anti-cd28 antibodies and use thereof - Google Patents

Silensed anti-cd28 antibodies and use thereof

Info

Publication number
HUP0400697A3
HUP0400697A3 HU0400697A HUP0400697A HUP0400697A3 HU P0400697 A3 HUP0400697 A3 HU P0400697A3 HU 0400697 A HU0400697 A HU 0400697A HU P0400697 A HUP0400697 A HU P0400697A HU P0400697 A3 HUP0400697 A3 HU P0400697A3
Authority
HU
Hungary
Prior art keywords
silensed
antibodies
silensed anti
Prior art date
Application number
HU0400697A
Other languages
English (en)
Hungarian (hu)
Original Assignee
Astellas Pharma Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Astellas Pharma Inc filed Critical Astellas Pharma Inc
Publication of HUP0400697A2 publication Critical patent/HUP0400697A2/hu
Publication of HUP0400697A3 publication Critical patent/HUP0400697A3/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P41/00—Drugs used in surgical methods, e.g. surgery adjuvants for preventing adhesion or for vitreum substitution
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/54—F(ab')2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/55—Fab or Fab'
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Transplantation (AREA)
  • Surgery (AREA)
  • Peptides Or Proteins (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
HU0400697A 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof HUP0400697A3 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US25515500P 2000-12-14 2000-12-14
PCT/US2001/047955 WO2002047721A1 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Publications (2)

Publication Number Publication Date
HUP0400697A2 HUP0400697A2 (hu) 2004-06-28
HUP0400697A3 true HUP0400697A3 (en) 2007-05-02

Family

ID=22967074

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0400697A HUP0400697A3 (en) 2000-12-14 2001-12-14 Silensed anti-cd28 antibodies and use thereof

Country Status (18)

Country Link
EP (1) EP1341553A4 (ko)
JP (1) JP2004515243A (ko)
KR (1) KR20040020866A (ko)
CN (1) CN1272345C (ko)
AR (1) AR031924A1 (ko)
AU (2) AU2608602A (ko)
BR (1) BR0116686A (ko)
CA (1) CA2432736A1 (ko)
CZ (1) CZ20031909A3 (ko)
HU (1) HUP0400697A3 (ko)
IL (1) IL156262A0 (ko)
MX (1) MXPA03005327A (ko)
NO (1) NO20032542L (ko)
NZ (1) NZ526569A (ko)
PL (1) PL363239A1 (ko)
RU (1) RU2261723C2 (ko)
WO (1) WO2002047721A1 (ko)
ZA (1) ZA200305384B (ko)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2002066059A2 (en) 2001-02-16 2002-08-29 Genetics Institute, Llc Agents that specifically block cd28-mediated signaling and uses therefor
US20080095774A1 (en) * 2001-02-16 2008-04-24 Wyeth Agents and Methods for Specifically Blocking CD28-Mediated Signaling
EP1909831A4 (en) 2005-06-14 2013-02-20 Amgen Inc PREPARATIONS OF SPONTANEOUS TAMPING PROTEINS
FR2951176A1 (fr) * 2009-10-09 2011-04-15 Tcl Pharma Ligands monovalents du recepteur cd28 humain
DK2536764T3 (en) * 2010-02-18 2018-09-17 Ose Immunotherapeutics ANTI-CD28 HUMANIZED ANTIBODIES
JP6884858B2 (ja) 2016-10-21 2021-06-09 アムジエン・インコーポレーテツド 医薬製剤及びその製造方法
AU2019287765A1 (en) 2018-06-15 2021-01-07 Flagship Pioneering Innovations V, Inc. Increasing immune activity through modulation of postcellular signaling factors
JP2022525332A (ja) * 2019-03-14 2022-05-12 ビオンド バイオロジクス リミテッド 免疫抑制の方法
WO2020227159A2 (en) 2019-05-03 2020-11-12 Flagship Pioneering Innovations V, Inc. Methods of modulating immune activity
JP2023509359A (ja) 2019-12-17 2023-03-08 フラグシップ パイオニアリング イノベーションズ ブイ，インコーポレーテッド 鉄依存性細胞分解の誘導物質との併用抗癌療法
EP4172323A1 (en) 2020-06-29 2023-05-03 Flagship Pioneering Innovations V, Inc. Viruses engineered to promote thanotransmission and their use in treating cancer
JP2023538891A (ja) 2020-08-19 2023-09-12 ゼンコア インコーポレイテッド 抗ｃｄ２８組成物
KR20230165276A (ko) 2021-03-31 2023-12-05 플래그쉽 파이어니어링 이노베이션스 브이, 인크. 타노트랜스미션 폴리펩티드 및 암의 치료에서의 이의 용도
AU2022303363A1 (en) 2021-06-29 2024-01-18 Flagship Pioneering Innovations V, Inc. Immune cells engineered to promote thanotransmission and uses thereof
WO2024040194A1 (en) 2022-08-17 2024-02-22 Capstan Therapeutics, Inc. Conditioning for in vivo immune cell engineering
WO2024077191A1 (en) 2022-10-05 2024-04-11 Flagship Pioneering Innovations V, Inc. Nucleic acid molecules encoding trif and additionalpolypeptides and their use in treating cancer
WO2024148336A1 (en) * 2023-01-06 2024-07-11 Igm Biosciences, Inc. T cell costimulatory multimeric binding molecules and uses thereof
US20240269251A1 (en) 2023-01-09 2024-08-15 Flagship Pioneering Innovations V, Inc. Genetic switches and their use in treating cancer

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5580756A (en) * 1990-03-26 1996-12-03 Bristol-Myers Squibb Co. B7Ig fusion protein

Also Published As

Publication number Publication date
IL156262A0 (en) 2004-01-04
PL363239A1 (en) 2004-11-15
AU2002226086C1 (en) 2006-03-09
EP1341553A1 (en) 2003-09-10
JP2004515243A (ja) 2004-05-27
CZ20031909A3 (cs) 2003-11-12
WO2002047721A1 (en) 2002-06-20
MXPA03005327A (es) 2004-12-03
RU2003121231A (ru) 2005-02-10
CA2432736A1 (en) 2002-06-20
AU2002226086B2 (en) 2005-08-25
NO20032542D0 (no) 2003-06-05
RU2261723C2 (ru) 2005-10-10
AR031924A1 (es) 2003-10-08
EP1341553A4 (en) 2004-07-28
CN1489473A (zh) 2004-04-14
CN1272345C (zh) 2006-08-30
ZA200305384B (en) 2004-10-11
HUP0400697A2 (hu) 2004-06-28
BR0116686A (pt) 2003-12-30
AU2608602A (en) 2002-06-24
NZ526569A (en) 2005-07-29
NO20032542L (no) 2003-08-07
KR20040020866A (ko) 2004-03-09

Similar Documents

Publication Publication Date Title
HK1208705A1 (en) Multivalent antibodies and uses therefor
TWI316088B (en) Anti-tnf alpha antibodies and their uses
GB0029360D0 (en) Humanised antibodies and uses thereof
IL225633A0 (en) Antibodies against alpha v beta 6 and uses thereof
EP1551447A4 (en) ANTI-ADDL ANTIBODIES AND USES THEREOF
IL154325A (en) Isolated anti-il-12 antibody and composition comprising the same
GB9927332D0 (en) Novel antibody and uses thereof
AU2608602A (en) Silensed anti-cd28 antibodies and use thereof
IL156161A0 (en) Substituted 2-anilino-benzimidazoles and the use thereof as nhe-inhibitors
GB0007333D0 (en) Novel compounds and their manufacture and use
AU2003219093A8 (en) Anti-hpv-16 e7 antibodies and their use
EP1589033A4 (en) ANTIBODY AND ITS USE
IL166063A0 (en) Antibodies and uses thereof
GB0026134D0 (en) Peptides and their use
EP1302770A4 (en) PARTICLE MARKING PROTEIN AND IMMUNO-CHROMATOGRAPHER USING THE SAME
GB0021497D0 (en) Compounds and their use
GB0007530D0 (en) Trityl-type compounds and their use
EP1627888A4 (en) ANTIBODY AND ITS USE
EP1437367A4 (en) ANTIBODIES AND ITS USE
GB0003527D0 (en) Antibodies
GB0005071D0 (en) Antibodies
GB0227080D0 (en) Antibodies and uses thereof
GB0002559D0 (en) Virulencegene and protein and their use
GB0016824D0 (en) Human monoclonal antibodies
GB0017139D0 (en) Human monoclonal antibodies

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: ASTELLAS PHARMA INC., JP

Free format text: FORMER OWNER(S): FUJISAWA PHARMACEUTICAL CO., LTD., JP

FD9A Lapse of provisional protection due to non-payment of fees